Does a Mandatory Non-Medical Switch From Originator to Biosimilar Infliximab Lead to Increased Use of Outpatient Healthcare Resources? A Register-Based Study in Patients With Inflammatory Arthritis

RMD Open- United Kingdom

doi 10.1136/rmdopen-2018-000710

Full Text

Abstract

Available in

Date

Authors

Publisher

BMJ

Related search

Observational Study of Inflammatory Arthritis Treatment by Etanercept Originator Switched to an Etanercept Biosimilar

Reumatologia
RheumatologyAllergyImmunology
2019English

FRI0103 One-Year Follow-Up of a Nationwide Cohort of Patients With Inflammatory Arthritis, Who Switched From Originator to Biosimilar Etanercept, Focusing on Patients Who Switched Back to Originator. An Observational Danbio Study

2018English

Switching Maintenance Infliximab Therapy to Biosimilar-Infliximab Does Not Lead to Significant Changes in Health-Related Quality of Life and Clinical Outcomes in Inflammatory Bowel Disease Patients

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Response To: ‘Mandatory, Cost-Driven Switching From Originator Etanercept to Its Biosimilar SB4: Possible Fallout on Non-Medical Switching’ by Cantini and Benucci

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
2018English

Letter: Is There a Role for Infliximab Biosimilar in Patients With Inflammatory Bowel Disease With Secondary Loss of Response to Infliximab Innovator?

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2018English

Increased Risk for Chronic Comorbid Disorders in Patients With Inflammatory Arthritis: A Population Based Study

BMC Family Practice
Family Practice
2013English

Efficacious Transition From Reference Infliximab to Biosimilar Infliximab in Clinical Practice

International Journal of Rheumatic Diseases
Rheumatology
2019English

Pms73 - Bright Future for the Use of Biosimilar Infliximab: Evidence-Based Analysis Using Healthcare Claim Database

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pregnancy Outcomes in Women With Inflammatory Bowel Disease Treated With Biosimilar Infliximab

Gastroenterologie a Hepatologie
HepatologyGastroenterology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy